UBS lowered the firm’s price target on Linde to $475 from $490 and keeps a Neutral rating on the shares. After a review of price and volume trends and updates on chemical spreads and prices, the firm’s Q2 estimates are reduced about 2% in aggregate across its North American Chemicals coverage, the analyst tells investors in an earnings preview note for the group.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.